<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00765453</url>
  </required_header>
  <id_info>
    <org_study_id>07/Q0603/76</org_study_id>
    <secondary_id>2007-002-144</secondary_id>
    <nct_id>NCT00765453</nct_id>
  </id_info>
  <brief_title>Bone Marrow Derived Adult Stem Cells for Acute Anterior Myocardial Infarction</brief_title>
  <acronym>REGEN-AMI</acronym>
  <official_title>Randomised Controlled Clinical Trial of the Use of Autologous Bone Marrow Derived Progenitor Cells to Salvage Myocardium in Patients With Acute Anterior Myocardial Infarction</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Barts &amp; The London NHS Trust</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University College, London</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Queen Mary University of London</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Barts &amp; The London NHS Trust</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Study hypothesis :

      The purpose of this study is to determine whether Intracoronary infusion of autologous bone
      marrow derived progenitor cells to patients undergoing primary angioplasty for acute anterior
      myocardial infarction will lead to an improvement in cardiac function greater than that seen
      by placebo alone.

      Aims

        -  To demonstrate that it is safe and feasible to deliver autologous bone marrow derived
           stem cells within hours of the primary angioplasty procedure

        -  To demonstrate the effects of autologous bone marrow derived stem cells on cardiac
           function using cardiac MRI (or cardiac CT), echocardiography and left ventriculography.

        -  To demonstrate the effect of autologous bone marrow derived stem cells in addition to
           standard care leads to improvement in cardiac function compared to patients
           saline(placebo) and standard care.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>March 2008</start_date>
  <completion_date type="Anticipated">March 2018</completion_date>
  <primary_completion_date type="Actual">March 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Longitudinal change in left ventricular function (ejection fraction)</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Longitudinal change in left ventricular function (ejection fraction), change in left ventricular end systolic volume, and change in infarct size</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Longitudinal change in left ventricular function as measured by LV angiography</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Longitudinal change in left ventricular function assessed by echocardiography.</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in left ventricular end systolic volume and change in infarct size.</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Longitudinal change in left ventricular function assessed by echocardiography.</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MACE</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life</measure>
    <time_frame>6 and 12 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Acute Myocardial Infarction</condition>
  <arm_group>
    <arm_group_label>Intracoronary</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will be randomised in a 1:1 ratio to receive intracoronary injections of bone marrow derived stem/progenitor cells or placebo infusion through a percutaneous route</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo infusion</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Bone marrow derived progenitor cells or placebo infusion</intervention_name>
    <description>Over-the-wire balloon catheter delivers infusion into coronary vessel using a stop-flow technique</description>
    <arm_group_label>Intracoronary</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo infusion</intervention_name>
    <description>Placebo infusion</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients presenting to the Heart Attack Centre with acute anterior myocardial
             infarction (ST elevation in at least 2 contiguous anterior leads ≥ 0.2 mV) and treated
             with acute PCI with stent implantation within 24 hours after symptom onset

          -  Acute PCI / stent implantation has been successful (residual stenosis visually &lt; 30%
             and TIMI flow ≥ 2).

          -  At the time of inclusion patient no longer requires i.v. catecholamines or mechanical
             hemodynamic support (aortic balloon pump)

          -  Significant regional wall motion abnormality in LV angiogram at the time of acute PCI
             in the LAD territory

          -  Age 18 - 80 Years (primary angioplasty confers an adverse prognosis in those over the
             age of 80 years)

          -  Written informed consent in the recruiting centres native language

        Exclusion Criteria:

          -  Regional wall motion abnormality outside the area involved in the index acute
             myocardial infarction

          -  Need to revascularise additional vessels, outside the infarct artery as a planned
             procedure (these vessels can be treated at baseline)

          -  Arteriovenous malformations or aneurysms

          -  Active infection, or fever or diarrhoea within last 4 weeks

          -  Chronic inflammatory disease

          -  Known HIV infection or active hepatitis

          -  Neoplastic disease without documented remission within the past 5 years

          -  Cerebrovascular insult within 3 months

          -  Impaired renal function (creatinine &gt; 200mmol) at the time of cell therapy

          -  Significant liver disease (GOT &gt; 2x upper limit) or spontaneous INR &gt; 1,5)

          -  Anemia (hemoglobin &lt; 8.5 mg/dl)

          -  Platelet count &lt; 100.000/µl

          -  Hypersplenism

          -  Known allergy or intolerance to clopidogrel, heparin or abciximab

          -  History of bleeding disorder

          -  Gastrointestinal bleeding within 3 months

          -  Major surgical procedure or trauma within 2 months

          -  Uncontrolled hypertension

          -  Pregnancy

          -  Mental retardation leading to inability to obtain informed consent

          -  Previously performed stem / progenitor cell therapy

          -  Participation in another clinical trial within the last 30 days
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anthony Mathur, FRCP FESC Ph</last_name>
    <role>Principal Investigator</role>
    <affiliation>Barts and the London NHS Trust</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Rigshopitalet, Unversity of Copenhagen</name>
      <address>
        <city>Copenhagen</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire Vaudois</name>
      <address>
        <city>Lausanne</city>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>London Chest Hospital, Barts and The London NHS Trust</name>
      <address>
        <city>Bethnal Green</city>
        <state>London</state>
        <zip>E2 9JX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Heart Hosptial, UCLH Foundation Trust</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Royal Free Hospital, Royal Free London Foundation Trust</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
    <country>Switzerland</country>
    <country>United Kingdom</country>
  </location_countries>
  <link>
    <url>http://www.bartsandthelondon.nhs.uk/HAC/heart_stem_cell_research.asp</url>
    <description>Click here for information on our cardiac stem cell trials</description>
  </link>
  <verification_date>August 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 2, 2008</study_first_submitted>
  <study_first_submitted_qc>October 2, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 3, 2008</study_first_posted>
  <last_update_submitted>August 6, 2015</last_update_submitted>
  <last_update_submitted_qc>August 6, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 7, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Barts &amp; The London NHS Trust</investigator_affiliation>
    <investigator_full_name>Anthony Mathur</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Heart attack</keyword>
  <keyword>Anterior Myocardial infarction (MI)</keyword>
  <keyword>adult stem cells</keyword>
  <keyword>bone marrow progenitor cells</keyword>
  <keyword>bone marrow stem cells</keyword>
  <keyword>autologous</keyword>
  <keyword>left ventricular function</keyword>
  <keyword>intracoronary injection</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infarction</mesh_term>
    <mesh_term>Myocardial Infarction</mesh_term>
    <mesh_term>Anterior Wall Myocardial Infarction</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

